About OraPharma
OraPharma is a company based in Bridgewater (United States) founded in 1997 was acquired by Bausch Health in June 2012. OraPharma has raised $16 million across 1 funding round from investors including Bausch Health, Frazier Healthcare Partners and Canaan. OraPharma offers products and services including Arestin and OSSIX Portfolio. OraPharma operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Bridgewater, United States
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Orapharma Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$16 M (USD)
in 1 rounds
-
Latest Funding Round
$16 M (USD), Series C
Dec 14, 1998
-
Investors
Bausch Health
& 7 more
-
Employee Count
Not available
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of OraPharma
OraPharma offers a comprehensive portfolio of products and services, including Arestin and OSSIX Portfolio.
Antibacterial microspheres for managing gum disease in patients.
Regenerative materials for bone and tissue grafting procedures.
People of OraPharma
Unlock access to complete
Unlock access to complete
Software Development Team
294 people
Leadership Team
141 people
Senior Team
50 people
Finance and Accounting
45 people
Data Analysis and Operations Team
41 people
Product Management Team
26 people
Legal and Compliance
26 people
Human Resources and Administration
26 people
Unlock access to complete
Funding Insights of OraPharma
OraPharma has successfully raised a total of $16M through 1 strategic funding round. The most recent funding activity was a Series C round of $16 million completed in December 1998. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in OraPharma
OraPharma has secured backing from 8 investors, including venture fund investors. Prominent investors backing the company include Bausch Health, Frazier Healthcare Partners and Canaan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Canaan is recognized as an early-stage venture capital firm.
|
Locked | Locked | Locked | |
|
Early-stage companies are invested in globally by TL Ventures.
|
Locked | Locked | Locked | |
|
Life science & tech focused VC firm investing in the US
|
Locked | Locked | Locked |
Investor details for OraPharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OraPharma
Investment portfolio details for OraPharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - OraPharma
Detailed financials for OraPharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Orapharma Comparisons
Peer comparison for OraPharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of OraPharma
OraPharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of OraPharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Orapharma
Complete news archive for OraPharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OraPharma
OraPharma was founded in 1997 and raised its 1st funding round 1 year after it was founded.
OraPharma is headquartered in Bridgewater, United States. It is registered at Bridgewater, New Jersey, United States.
OraPharma is a funded company, having raised a total of $16M across 1 funding round to date.
OraPharma is developing products that help improve and maintain oral health. ARESTIN (minocycline HCl) Microspheres, 1 mg is a locally administered antibiotic (LAA) offering a patented microsphere technology for the treatment of periodontitis as an adjunct to scaling and root planing. Another product ONSET, a delivery system of locally buffered anesthesia that can provide faster onset of anesthesia and more comfortable injection. Other products include EZ white for whitening, ossix plus for tissue regeneration, and neutrasal for dryness of oral mucosa.
OraPharma's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
OraPharma offers Arestin and OSSIX Portfolio.
OraPharma has 8 investors. Key investors include Bausch Health, Frazier Healthcare Partners, Canaan, TL Ventures, and Domain Associates.